Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Revenue (2021 - 2025)

Historic Revenue for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.5 billion.

  • Rxo's Revenue fell 1187.76% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year increase of 2619.78%. This contributed to the annual value of $5.7 billion for FY2025, which is 2619.78% up from last year.
  • Rxo's Revenue amounted to $1.5 billion in Q4 2025, which was down 1187.76% from $1.4 billion recorded in Q3 2025.
  • In the past 5 years, Rxo's Revenue registered a high of $1.7 billion during Q4 2024, and its lowest value of $913.0 million during Q1 2024.
  • In the last 5 years, Rxo's Revenue had a median value of $1.2 billion in 2021 and averaged $1.2 billion.
  • As far as peak fluctuations go, Rxo's Revenue tumbled by 2301.83% in 2023, and later surged by 7044.99% in 2024.
  • Rxo's Revenue (Quarter) stood at $1.3 billion in 2021, then fell by 15.6% to $1.1 billion in 2022, then fell by 12.68% to $978.0 million in 2023, then skyrocketed by 70.45% to $1.7 billion in 2024, then dropped by 11.88% to $1.5 billion in 2025.
  • Its Revenue was $1.5 billion in Q4 2025, compared to $1.4 billion in Q3 2025 and $1.4 billion in Q2 2025.